Results 101 to 110 of about 1,815 (184)

Analysis of efficacy of SGLT2 inhibitors using semi-mechanistic model

Frontiers in Pharmacology, 2014
Renal sodium-dependent glucose co-transporter 2 (SGLT2) is one of the most promising targets for the treatment of type 2 diabetes. Two SGLT2 inhibitors, dapagliflozin and canagliflozin, have already been approved for use in USA and Europe; several ...
Oleg eDemin Jr, Tatiana eYakovleva, Dmitry eKolobkov, Oleg eDemin   +3 more
doaj   +1 more source

Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects

Journal of Pharmacological Sciences, 2016
The sodium-glucose cotransporter (SGLT) 2 offer a novel approach to treating type 2 diabetes by reducing hyperglycaemia via increased urinary glucose excretion.
Atsuo Tahara, Toshiyuki Takasu, Masanori Yokono, Masakazu Imamura, Eiji Kurosaki   +4 more
doaj   +1 more source

Progranulin deficiency exacerbates kidney inflammation and autophagic flux via increased mTORC1 activity under diabetic condition [PDF]

, 2023
順天堂大学博士（医学）2022年度doctoral ...
サクマ, ヒロコ, 作間, 宏子
core  

A review of the effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on lean body mass in humans [PDF]

, 2019
Weight loss is an important goal in the management of several chronic conditions, including type 2 diabetes mellitus, and pharmacological therapies that aid weight loss are appealing.
Jack Sargeant (7623326), James King (1252200), Joseph Henson (477838), Kamlesh Khunti (171607), Melanie Davies (545715), Thomas Yates (171609)   +5 more
core   +2 more sources

Long-term Effects of Ipragliflozin on Adipose Tissue in Japanese Patients with Obese Type 2 Diabetes [PDF]

, 2018
Article信州医学雑誌 66(1): 29-37(2018)journal ...
Komatsu, Mitsuhisa, Nishio, Shin-ichi, Ohkubo, Yohsuke, Oiwa, Ako, Sekido, Takashi   +4 more
core   +1 more source

Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial [PDF]

, 2022
Aims To examine the effects of a 24-month treatment with ipragliflozin on carotid intima-media thickness (IMT) in type 2 diabetes patients. Methods and results In this multicenter, prospective, randomized, open-label, and blinded-endpoint investigator ...
173932/profile-ja.html, 309, 501, 60271144, 80345214, Eguchi, Kazuo, Ishizu, Tomoko, Kanzaki, Yumiko, Kitakaze, Masafumi, Matsunaga, Kazuo, Murohara, Toyoaki, Node, Koichi, Okada, Yosuke, Sata, Masataka, Shimabukuro, Michio, Taguchi, Isao, Tanaka, Atsushi, Teragawa, Hiroki, Ueda, Shinichiro, Yoshida, Hisako, イシヅ, トモコ, イシヅ, トモコ, ウエダ, シンイチロウ, ウエダ, シンイチロウ, エグチ, カズオ, エグチ, カズオ, オカダ, ヨウスケ, オカダ, ヨウスケ, カンザキ, ユミコ, カンザキ, ユミコ, キタカゼ, マサフミ, キタカゼ, マサフミ, サタ, マサタカ, シマブクロ, ミチオ, タグチ, イサオ, タグチ, イサオ, タナカ, アツシ, タナカ, アツシ, テラガワ, ヒロキ, テラガワ, ヒロキ, ノデ, コウイチ, ノデ, コウイチ, マツナガ, カズオ, マツナガ, カズオ, ムロハラ, トヨアキ, ムロハラ, トヨアキ, ヨシダ, ヒサコ, ヨシダ, ヒサコ, 佐田, 政隆, 島袋, 充生   +49 more
core  

Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials [PDF]

, 2017
Aim To compare the associations of individual sodium-glucose co-transporter-2 (SGLT2) inhibitors with adverse renal outcomes in patients with type 2 diabetes mellitus (T2DM).
Li, Dandan, Li, Yufeng, Song, Yiqing, Tang, Huilin, Wang, Tiansheng, Zhai, Suodi, Zhang, Jingjing   +6 more
core   +1 more source

Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice

Journal of Pharmacological Sciences, 2016
Previously we investigated the pharmacokinetic, pharmacodynamic, and pharmacologic properties of all six sodium-glucose cotransporter (SGLT) 2 inhibitors commercially available in Japan using normal and diabetic mice.
Atsuo Tahara, Toshiyuki Takasu, Masanori Yokono, Masakazu Imamura, Eiji Kurosaki   +4 more
doaj   +1 more source

SGLT2阻害薬の抗動脈硬化作用 : モデル動物を用いた検討 [PDF]

, 2016
学位の種別: 課程博士審査委員会委員 : （主査）東京大学教授 南学 正臣, 東京大学准教授 吉内 一浩, 東京大学准教授 柿木 章伸, 東京大学准教授 加藤 聡, 東京大学講師 伊地知 秀明University of Tokyo ...
Iwamoto Masahiko, 岩本 真彦
core   +1 more source

Assessment of benefits and risks of sodium-glucose co-transporter 2 inhibitors in metabolic complications [PDF]

, 2019
Sodium-glucose co-transporter 2 (SGLT2) inhibitors (e.g. canagliflozin, dapagliflozin, empagliflozin, ertugliflozin) have been recently approved for type 2 diabetes mellitus (T2DM) treatment, a metabolic disease affecting a huge number of persons ...
Oliveira, Ricardo Filipe Silva de
core